API Product

Salmeterol Xinafoate

salmeterol-xinafoate
Product Status:
Commercial
Available Grades:
  • Inhalation
Regulatory Status:
DMF
CEP
Production Sites:
  • Hovione Loures
Product Type:
  • LABA
CAS Number:
94749-08-3
Modes of Application:
  • Inhalation
Common Indications:
  • Asthma
  • COPD
Last Inspection:
FDA May 2018

Hovione can customize Salmeterol Xinafoate for inhalation with an unrivalled range of particle size reduction technologies for the production of tailor made API, featuring a near-perfect particle size distribution reproducibility with a low span and amorphous content, providing highly stable API.

Hovione Salmeterol Xinafoate is approved in generic applications.

With a proven track record in developing and manufacturing high performance APIs Hovione offers a full range of API for inhalation, e.g. Fluticasone Propionate or Tiotropium Bromide.

 

 

 


This is not to be construed as a representation of non-infringement or as an offer to sell in those countries where such would constitute an infringement of third parties’ patent rights.

Related files

Hovione Product Portfolio
pdf (84.51 KB)
Download